ASCIA COVID-19 information

This webpage has been developed in response to the COVID-19 pandemic caused by the spread of coronavirus (SARS-CoV-2) infections. Content last updated February 2022.

This webpage includes links to the following information:

COVID-19 vaccine information | Govt COVID-19 information | Information from other organisations COVID-19 and Telehealth | Medical product supply updates | IUIS  COVID-19 Primary Immunodeficiency Survey | COVID–19 Global Rheumatology Alliance Registry | ASCIA COVID-19 Working Party | Healthdirect COVID-19 Symptom Checker | Healthdirect COVID-19 Restriction Checker | COVID-19 Dashboard | Australia-COVID-19-current-situation-and-case-numbers | SBS Translations of Coronavirus Information 

COVID-19 vaccine information 

ASCIA COVID-19 vaccine information  
Other COVID-19 vaccine information

Australian Technical Advisory Group on Immunisation (ATAGI) statement on the use of a third primary ‘booster’ dose of COVID-19 vaccine in severely immunocompromised people (prepared in consultation with ASCIA)

University of Melbourne VaxFACTS website COVID-19 vaccine Q&A videos

COVID-19 vaccination decision guide for women who are pregnant, breastfeeding, or planning pregnancy: AU Government

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
COVID-19 vaccine agreements, safety and approval: AU and NZ Governments

Other Information

ASCIA telehealth resources webpage

This webpage allows ASCIA members to have ready access to online ASCIA resources for use in telehealth and face to face consultations. 

Information from governments (AU, NZ) 


COVID-19 Living Guidelines are available at                            These high priority, evidence-based clinical COVID-19 guidelines are updated weekly with the latest research by the Australian government's National COVID-19 Clinical Evidence Task Force.  


Call the Coronavirus Health Information Line 1800 020 080 (24 hours a day, 7 days a week) or call Healthdirect Hotline 1800 022 22ll the new COVID-19 Health Professionals National Disability Advisory Service on 1800 131 330 (7am – 11pm AEST, 7 days a week). Calls to the Advisory Service will be answered by health professionals with disability service qualifications and experience working with people with disability. 

Healthdirect Australia has developed a COVID-19 Symptom Checker, an online self-guided tool to help people find out if they need to seek medical help.

COVID-19 Symptom Checker


Call the Government Helpline on 0800 779 997 (9am to 5pm, 7 days a week) if you are not sure what support is available, don’t know who to contact for help or would like more information. 

Information from other organisations 


Royal College of Pathologists of Australasia (RCPA) Position Statement about COVID-19 testing

Guidelines for the management of rheumatic diseases during the COVID-19 pandemic are being developed by the Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network, the Australian Rheumatology Association (ARA) and the Australian Living Evidence Consortium. ASCIA members are invited to complete a survey about what topics are of most importance for inclusion in these guidelines. The link to the survey is and it should take less than 15 minutes to complete.

Australian & New Zealand Childrens Haematology/Oncology Group (ANZCHOG)

National Health and Medical Research Council (NHMRC) COVID-19 clinical evidence taskforce 

Australasian Society for Infectious Diseases (ASID) including a statement about Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-COV-2 (PIMS-TS)

Australian and New Zealand Intensive Care Society (ANZICS)

Australasian College for Emergency Medicine (ACEM)

National Asthma Council (NAC) 

Asthma Australia

Allergy & Anaphylaxis Australia (A&AA)

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected  
pdf2020 WHO Clinical management suspected COVID-19855.57 KB23/03/2020, 04:17
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection. 
COVID-19 Global Cases. Center for Systems Science and Engineering, Johns Hopkins University. 2020
An interactive web-based dashboard to track COVID-19 in real time
UK PID Network 
CGD Society

COVID-19 and telehealth

The most up-to-date information regarding telehealth enabled items can be found at and further information regarding the COVID-19 National Health Plan can be found at

ASCIA Telehealth Resources  allow ASCIA members to have ready access to the latest versions of online ASCIA plans, checklists, forms and information for patients, for use in telehealth, as well as face to face consultations.  

Medical product supply updates

In response to the COVID-19 outbreak many suppliers of medical products are working to ensure the continuity of supply to patients in Australia and New Zealand, whilst also protecting the health of their employees. ASCIA is monitoring the situation and will post notices on this page from medical product suppliers and authorities, including the National Blood Authority (NBA) and the Theraputic Goods Administration (TGA).

NBA response to novel coronavirus 

TGA amendment to restrict hydroxychloroquine prescribing

ARRC letter to patients regarding hydroxychloroquine (Plaquenil) 

TGA critical medicine shortages in Australia

Adrenaline (epinephrine) autoinjector supply

Venom allergen supply

Other Medical Product Updates are available from suppliers here (AMSL, Bayer, Gamma Allergy, Mylan, Nutricia, Sanofi, Seqirus, Stallergenes Greer) 

IUIS primary immunodeficiency and COVID-19 survey

There is an urgent need to understand the impact of COVID-19 on immunodeficient and immunosuppressed patients. Whilst co-morbidities such as diabetes, cancer, arterial hypertension and heart disease have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for people with primary immunodeficiencies (PID).

ASCIA members are invited to complete the following surveys, that have been sent to ASCIA and other clinical immunology organisations by Professor Stuart Tangye, on behalf of the International Union of Immunological Societies (IUIS) Expert Committee of Inborn Errors of Immunity.

The link to the 2nd phase of the survey is

The link to the 1st phase of the survey is

The focus of the 1st phase of the survey is on obtaining top level of information, to get an idea of the number of affected PID patients and the impact of SARS CoV2.

The 2nd phase of the survey requires a greater level of information, for clinicians with affected/infected PID patients to complete.

The IUIS is conscious of the demands on time and resources due to COVID-19 on top of regular busy schedules and is grateful to all participating societies and organizations, which will all be acknowledged for their help and input into this initiative.

The surveys have been prepared by Professors Isabelle Meyts, Nizar Mahlaoui and Kate Sullivan, in conjunction with the European Society for Immunodeficiencies (ESID), the French national reference center for PID (CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires) and the International Patient Organisation for PID (IPOPI). The survey has been approved for global distribution.

COVID–19 Global Rheumatology Alliance registry

ASCIA is part of the COVID–19 Global Rheumatology Alliance. The mission of this alliance is to create a secure, de-identified, international case reporting registry and curate and disseminate the outputs from that registry. The COVID–19 Global Rheumatology Alliance physician-entered data registry is now available at 

This registry will facilitate the Alliance's primary goals, which are to:

  • Understand the outcomes of patients with rheumatologic conditions who develop COVID–19 infection and the influence of their comorbidities and medications on their outcomes.
  • Understand the influence of rheumatologic medications, such as hydroxychloroquine, on the outcomes of patients who develop COVID–19 infection.

The COVID–19 Global Rheumatology Alliance is interested in all cases, from asymptomatic to severely affected.

The Alliance aims to provide information back to doctors, patients, and researchers about how rheumatic disease patients and those treated with rheumatology drugs fare when they get infected. Data collected will potentially provide valuable information going forward to help make decisions about how to direct further studies and treat our patients.

ASCIA COVID-19 Working Party 

Since early March 2020, ASCIA  has been extremely acitive developing and updating ASCIA COVID-19 resources. The ASCIA COVID-19 working party comprises the members listed below, and is coordinated by the ASCIA CEO, Jill Smith. 

Chair: Dr Theresa Cole (VIC) - ASCIA Immunodeficiency committee Chair and ASCIA President Elect

Deputy Chair: Dr Paul Gray (NSW)


Prof Michaela Lucas (WA) - ASCIA President 

Dr Brynn Wainstein (NSW) - Immediate past ASCIA President 

Dr Michael O’Sullivan (WA) - ASCIA Director

A/Prof Jane Peake (QLD) - ASCIA Director

Dr Patrick Quinn (SA) - ASCIA Immunodeficiency committee Deputy Chair

Dr Dean Tey (VIC) - ASCIA 2021 Conference Chair

A/Prof Mike Gold (SA)

Dr Pravin Hissaria (SA)

Dr Kuang Hsiao (NZ)

Dr Miriam Hurst (NZ)

Prof Connie Katelaris AM (NSW)

Dr Karuna Keat (NSW)

Dr Daman Langguth (QLD)

Dr Andrew McLean-Tooke (WA) - Chair, ASCIA COVID-19 vaccine Working Group

Dr Ray Mullins (ACT)

A/Prof Kirsten Perrett (VIC)

Dr William Smith (SA)

Dr Melanie Wong (NSW)

Content updated February 2022


Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.